Last month, researchers from around the globe met for the ESMO Virtual Congress 2020. The meeting, held virtually due to the ongoing pandemic, highlighted important research in oncology, including significant updates on the impact of COVID-19 on cancer care, diagnosis and burden.
Other highlights from the meeting include data on new combinations for gastric and breast cancers that could shift the standard of care.
MD /alert compiled a list of the top 5 abstracts you can’t miss.
ESMO 2020 Congress Highlights Impact of COVID-19 on Cancer Care.
READ MORE.
Abemaciclib Represents ‘New Standard of Care’ for Patients With High-Risk Early Breast Cancer.
READ MORE.
Nivolumab Plus Chemotherapy ‘Potential New Standard of Care’ for Patients With Advanced, Metastatic Gastric Cancers.
READ MORE.
Vibostolimab, Pembrolizumab Combination Safe, Effective for Patients With Advanced NSCLC.
READ MORE.
Nivolumab, Cabozantinib Combination Improves PFS, ORR in Patients With Advanced RCC.
READ MORE.
